{
    "clinical_study": {
        "@rank": "121172", 
        "acronym": "PCC", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo daily for 4 weeks"
            }, 
            {
                "arm_group_label": "Sildenafil", 
                "arm_group_type": "Active Comparator", 
                "description": "50mg sildenafil daily for 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blinded, placebo-controlled trial in men and women, 40-75 years old,\n      diagnosed with pancreatic or cholangiocarcinoma cancer. Patients will receive placebo or\n      sildenafil daily for 4 weeks during their initial chemotherapy cycle."
        }, 
        "brief_title": "Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer", 
        "condition": [
            "Pancreatic Cancer", 
            "Cholangiocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pancreatic Neoplasms", 
                "Cholangiocarcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women, aged 40-75 years.\n\n          2. Diagnosed with Stage III or IV pancreatic or cholangiocarcinoma receiving the\n             following therapy:\n\n               -  Neoadjuvant chemotherapy\n\n               -  Surgical resection followed by chemotherapy.\n\n          3. Able to comprehend risks and sign a consent form.\n\n          4. Performance Status of 0-2.\n\n        Exclusion Criteria:\n\n          1. Significant renal or heart disease or any acute metabolic disease.\n\n          2. Evidence of hepatitis as indicated by a 3-fold increase in of 2 out of 3 liver\n             enzymes.\n\n          3. Diabetes mellitus or other untreated endocrine disease.\n\n          4. Recent (within 3 months) treatment with anabolic steroids.\n\n          5. Ongoing anticoagulant therapy.\n\n          6. Androgen secreting tumors of the ovary and adrenal or any ovarian tumor (e.g.,\n             Sertoli-Leydig).\n\n          7. Polycystic ovary syndrome (PCOS) and/or hyperthecosis.\n\n          8. Non-classical adrenal hyperplasia.\n\n          9. Cushing's syndrome.\n\n         10. Glucocorticoid resistance.\n\n         11. Pregnancy.\n\n         12. Hyperprolactinoma, hypothyroidism.\n\n         13. Use of nitrates.\n\n         14. Use of alpha blockers.\n\n         15. Use of protease inhibitors.\n\n         16. Use of cytochrome p450 inhibitors.\n\n         17. Systolic blood pressure <100 or >150, diastolic blood pressure <60 or >90.  This\n             range is smaller than the acceptable range stated in the prescribing information for\n             sildenafil (>90/50 and <170/110).\n\n         18. Peripheral vascular disease.\n\n         19. Use of a phosphodiesterase 5 inhibitor.\n\n         20. Any other circumstance deemed exclusionary by the PI or study physician."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106871", 
            "org_study_id": "13-0409"
        }, 
        "intervention": {
            "arm_group_label": "Sildenafil", 
            "description": "50mg of Sildenafil daily for 4 weeks", 
            "intervention_name": "Sildenafil", 
            "intervention_type": "Drug", 
            "other_name": "Viagra"
        }, 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cancer", 
            "pancreas", 
            "cholangiocarcinoma", 
            "fatigue", 
            "sildenafil", 
            "lean mass", 
            "muscle"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "contact": {
                "email": "kmrandol@utmb.edu", 
                "last_name": "Kate Randolph, BS", 
                "phone": "409-772-8126"
            }, 
            "facility": {
                "address": {
                    "city": "Galveston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77555"
                }, 
                "name": "The University of Texas Medical Branch"
            }, 
            "investigator": {
                "last_name": "Melinda Sheffield-Moore, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I Assessment of NO Mediated Signaling in Cancer Cachexia", 
        "overall_contact": {
            "email": "kmrandol@utmb.edu", 
            "last_name": "Kate M Randolph, BS", 
            "phone": "409-772-8126"
        }, 
        "overall_contact_backup": {
            "email": "cpdanesi@utmb.edu", 
            "last_name": "Christopher Danesi, MS", 
            "phone": "409-772-8126"
        }, 
        "overall_official": {
            "affiliation": "University of Texas", 
            "last_name": "Melinda Sheffield-Moore, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Lean body mass will be measured by DEXA scan", 
                "measure": "Lean Body Mass", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Skeletal muscle fatigue will be measured by leg dynamometer.", 
                "measure": "Skeletal Muscle Fatigue", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106871"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas, Galveston", 
            "investigator_full_name": "Melinda Sheffield Moore", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "The University of Texas, Galveston", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of Texas, Galveston", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}